Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tralokinumab - LEO Pharma

Next Previous
Drug Profile

Tralokinumab - LEO Pharma

Alternative Names: Adbry; Adtralza; CAT-354; LP 0162; Tralokinumab-ldrm - AstraZeneca

Latest Information Update: 01 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Karolinska University Hospital; LEO Pharma; MedImmune
  • Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis
  • Discontinued Alopecia areata; Asthma; Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Ulcerative colitis

Most Recent Events

  • 17 Nov 2025 Efficacy and adverse events data from a phase III ADHAND trial in Atopic dermatitis released by LEO Pharma
  • 09 Jul 2025 Efficacy and adverse event data from the phase IIIb ADHAND trial in Atopic dermatitis released by LEO Pharma
  • 25 Oct 2024 Final adverse events and efficacy data from the phase-III ECZTEND trial in Atopic dermatitis released by LEO Pharma ,

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top